Singapore-based biotech Hummingbird Bioscience has outlicensed its lead immunotherapy candidate, HMBD-002, to Australian drug ...

Bayer’s (BAYN: DE) cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and ...

Biogen’s (Nasdaq: BIIB) salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according ...

The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty ...

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

Australian biotech CSL Limited Europe-based subsidiary CSL Behring announced a milestone in the early benefit assessment of ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ...

PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop ...

Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...

Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine ...

Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its ...